DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Tuesday, April 27, 2010

Cetero Research : More Than 500 Diabetes Studies Completed

Cetero ResearchApril 13, 2010 - Full-Service Options Help Move Treatments Through Proof-of-Concept More Quickly – Cetero Research, the leading early-stage contract research organization (CRO), announced it has completed more than 500 diabetes research studies in the past three years for both Type 1 and Type 2 diabetics, including complex clamp studies and studies in Phase I, II, III and IV. Cetero is the only CRO that can combine both pivotal pharmacokinetic studies and proof-of-concept studies in one study, saving up to six months of development time.

“Approximately eight percent of the U.S. population struggles with diabetes, and the numbers continue to grow. Our ability to provide researchers with the support they need to expedite new drug development is extremely important,”... Cetero Research's Press Release -

Ampio Pharmaceuticals : Phase II Clinical Trial of Optina™ to Treat Diabetic Retinopathy

Ampio Pharmaceuticals, Inc.April 12, 2010 - Ampio Pharmaceuticals Contracts with St. Michael's Hospital to Conduct Phase II Clinical Trial of Optina™ to Treat Diabetic Retinopathy - Ampio Pharmaceuticals, Inc. (OTCBB: AMPE), announced the signing of a contract with St. Michael's Hospital, Toronto, Canada to conduct, "A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Three Doses of Oral Optina™ in Adult Subjects with Diabetic Macular Edema". This phase II trial will seek the optimal content of each dose using industry standard methods of Optical Coherence Tomography (OCT) and Best Corrected Visual Acuity (BCVA). The data will be used to construct a pivotal phase III trial for submission to regulatory bodies in the USA, Europe and Asia... Ampio Pharmaceuticals' Press Release -

Friday, April 16, 2010

Regulus Therapeutics : New Pre-clinical Data on microRNA Therapeutics for Diabetesce plasma glucose

Regulus TherapeuticsApril 15, 2010 - Targeting microRNA improves insulin resistance and glucose tolerance in mouse models of diabetes – Regulus Therapeutics Inc. announced that new data from its metabolic disease program were presented at the “Diabetes” Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice. The increased incidence of diabetes is a growing threat to global health, and microRNA therapeutics represent a promising strategy for the discovery and development of novel anti-diabetic agents.

Isis Pharmaceuticals
“Diabetes is a multi-factoral disease that results in disruption of the metabolic system. microRNA therapies that can modulate pathways of disease rather than single molecular targets represent a novel approach for diabetes,” ...

Alnylam Pharmaceuticals...

...About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from its founding companies Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS).... Regulus Therapeutics' Press Release - Alnylam Pharmaceuticals' Press Release - Isis Pharmaceuticals' Press Release -

Versartis New Data at International Congress on EndocrinologY

VersartisMarch 26, 2010 - Posters will Illustrate Progress of Company’s Drugs for Metabolic and Endocrine Diseases – Versartis, Inc., an emerging biotechnology company developing novel biologics for the treatment of patients with metabolic diseases, will present two scientific posters that demonstrate monthly dosing capabilities of the company’s lead product, VRS-859 (exenatide-XTEN), and earlier stage product, VRS-317 (hGH-XTEN), at the 14th Annual International Congress on Endocrinology (ICE 2010) beginning today in Kyoto, Japan.

Jeffrey Cleland, Ph.D., Founder and Chief Executive Officer of Versartis, said, “We are very encouraged by the potential of the novel XTEN technology to provide monthly dosing in preclinical studies. This new data validates our earlier research results and supports our plans for advancing both products into the clinic later this year.”

VRS-859, a once monthly dosage form of the GLP-1 analog exenatide, has demonstrated improved glycemic control over and comparable weight loss to an infusion of exenatide. VRS-859 is on track for a Phase 1a trial in type 2 diabetes patients to begin in the second quarter 2010. VRS-317, a once monthly dosage form of human growth hormone (hGH), has demonstrated superiority of dosing and tolerability over other long-acting hGH analogs... Versartis' Press Release -

ChemoCentryx : Phase II Clinical Trial of CCX140, a Novel, Orally-Available Small Molecule Antagonist of Chemokine Receptor CCR2

ChemoCentryxMarch 22, 2010 - Clinical Study Underway for Treatment of Type 2 Diabetes Mellitus — ChemoCentryx, Inc., announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2. This receptor has been shown to play a role in the inflammatory response associated with metabolic diseases including type 2 diabetes, as well as other diseases including vascular restenosis following stent placement, and multiple sclerosis.

Chronic inflammation is now thought to be central to the development of insulin resistance in type 2 diabetes. Macrophages represent as much as 40% of the cell population in obese adipose tissue; the majority of these macrophages are derived from CCR2-positive monocytes recruited from the blood. CCX140 is a potent and selective antagonist of the CCR2 chemokine receptor. CCX140 works by blocking the monocyte/macrophage infiltration that occurs during inflammation and thus is designed to provide selective treatment of the disease without compromising other immune functions.... ChemoCentryx's Press Release -

Tuesday, April 13, 2010

Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market

Roche13 April 2010 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Elron Electronics Ltd. (TASE:ELRN) announced that they have signed an agreement under which Roche will acquire 100% of Medingo Ltd., a majority-owned subsidiary of the Elron group. Medingo Ltd. is engaged in the development of a semi-disposable insulin patch pump.

Medingo Ltd.
Under the terms of the agreement, Roche will pay Medingo Ltd.’s shareholders an upfront payment of US$ 160 million as well as up to 25% of the upfront payment in performance related milestones... Roche's Press Release - [PDF] Elron Electronics' Press Release -

Monday, April 12, 2010

CureDM Partners Novel Diabetes Treatment with Sanofi-Aventis

Sanofi-AventisApril 8, 2010 – CureDM, LLC announced that an agreement has been signed with Sanofi-Aventis (EURONEXT: SAN and NYSE: SNY) for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

Sanofi-Aventis“We are extremely pleased to have the opportunity to partner with one of the most innovative global pharmaceutical companies,”... [PDF] CureDM's Press Release - [PDF] Sanofi-Aventis' Press Release -

SANUWAVE : Enrollment in dermaPACE Phase III Pivotal IDE Clinical Trial for the Treatment of Diabetic Foot Ulcers

SANUWAVE HealthApril 6, 2010 – SANUWAVE Health, Inc., (OTC BB: SNWV), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that patient enrollment was completed in March in its dermaPACE™ Phase III pivotal, randomized, double-blinded, sham controlled, multicenter clinical trial comparing its Pulsed Acoustic Cellular Expression (PACE™) technology, utilizing the dermaPACE™ tissue regeneration device, to sham control for the treatment of diabetic foot ulcers (DFU).
The primary study goal is to establish superiority in diabetic foot ulcer healing rates using the dermaPACE™ treatment compared to sham control, when both are combined with the current standard of care. The standard of care includes wet-to-dry dressings, the most widely used primary dressing material in the United States, and offloading with a walking boot... [PDF] SANUWAVE Health's Press Release -

PositiveID : Patent with the United States Patent and Trademark Office for its iGlucose System

PositiveID CorporationMar 23, 2010 - PositiveID Corporation (NASDAQ: PSID) announced that it has filed with the U.S. Patent and Trademark Office a non-provisional patent application for its iGlucose system, currently under development, which uses wireless SMS messaging to automatically communicate a diabetic patient's blood glucose levels from any data-capable glucose meter to an online database.

The iGlucose system is designed to communicate automatically with a wide variety of glucometers by utilizing electronics and stored information that will query and recognize a particular glucometer when connected to the device. This recognition aspect is unique because there are differences in how data is retrieved from different meters and manufacturers.

The iGlucose system also successfully addresses obstacles in SMS data transmission. Blood glucose and other data must be packed into a buffer to make most efficient use of the available bits, since SMS text messages are limited to 140 characters in a single message. Due to SMS transmission limitations, iGlucose utilizes proprietary data compression software and encryption algorithms to overcome these challenges... PositiveID's Press Release -

Medtronic : FDA Approval for Industry’s Most Advanced Integrated System for Diabetes Management

MedtronicMarch 17, 2010 - Next Generation Integrated System – MiniMed Paradigm® REAL-Time Revel™ System – Incorporates Predictive Alerts to Help Patients More Tightly Control Diabetes – Medtronic, Inc. (NYSE:MDT) announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm® REAL-Time Revel™ System, the next generation of the industry’s only integrated diabetes management system (insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software). The system incorporates new innovative CGM features including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events.

“Medtronic is extending its lead in the path towards the artificial pancreas with this next generation integrated system and our ongoing advancements in algorithm development,”... Medtronic's Press Release -

NexMed : Ability of Its NexACT® Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion

Bio-QuantNexMedMarch, Wednesday 17 2010 - NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection... NexMed's Press Release -